



07-20-06

IFW

10/825,898

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): William J. Boyle

Serial No.: 10/825,898

Group Art Unit No.: 1644

Filed: April 15, 2004

Examiner: Schwadron, Ronald B.

For: OSTEOPROTEGERIN BINDING PROTEINS AND  
RECEPTORS

Docket No.: A-451N

INFORMATION DISCLOSURE STATEMENT**Mail Stop Amendment**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant submits a "List of References Cited by Applicant" on a modified supplemental PTO-1449 form.

Applicant makes no determination of relevancy with respect to the references cited herewith and request the Examiner to make an independent determination of relevance and/or materiality of the reference.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications, or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/721,212, filed November 21, 2000. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).

Applicant's position regarding this information and its relevancy remains unchanged.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

**EXPRESS MAIL CERTIFICATE**

\*Express Mail® label number:

EL 732825391 US

Date of Deposit:

July 17, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop, the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dee Dee Sutherland

Printed Name


Dee Dee Sutherland

Signature

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Robert B. Winter  
Attorney for Applicant  
Registration No.: 34,456  
Phone: (805) 447-2425  
Date: July 17, 2006

Please send all future correspondence to:

US Patent Operations/ RBW  
Dept. 4300, M/S 28-2-C  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

Modified Form PTO-1449

Atty. Docket No.

A-451N

Serial No.

10/825,898

Applicant

William J. Boyle

Filing Date

April 15, 2004

Group

1644



(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	4,179,337	12/18/1979	Davis et al.			
	A2	5,763,223	06/09/1998	Wiley et al.			
	A3	5,843,678	12/01/1998	Boyle, William J.			
	A4	5,961,974	10/05/1999	Armitage et al.			
	A5	6,150,090	11/21/2000	Baltimore et al.			
	A6	6,410,516	06/05/2002	Baltimore et al.			
	A7	6,419,929	07/16/2002	Aderson, Dirk M.			
	A8	6,525,180	02/05/2003	Gorman et al.			
	A9	6,645,500	11/11/2003	Halkier et al.			
	A10	6,740,522 B2	05/25/2004	Anderson, Dirk M.			
	A11	6,884,598	04/26/2005	Dougall, William C.			
	A12	2003/0017151 A1	01/23/2003	Dougall et al.			
	A13	2003/0021785 A1	01/30/2003	Dougall et al.			
	A14	2003/0103978 A1	06/05/2003	Deshpande et al.			
	A15	2003/0104485 A1	06/05/2003	Boyle, William J.			
	A16	2003/0175840	09/18/2003	Yamaguchi et al.			
	A17	2003/0176647 A1	09/18/2003	Yamaguchi et al.			
	A18	2003/0208045 A1	11/06/2003	Yamaguchi et al.			
	A19	2005/0003457 A1	01/06/2005	Yamaguchi et al.			

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449		Atty. Docket No. A-451N	Serial No. 10/825,898
<b>LIST OF REFERENCES CITED BY APPLICANT</b>		Applicant William J. Boyle	
(Use several sheets if necessary)		Filing Date April 15, 2004	Group 1644

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION <u>YES</u> <u>NO</u>
	B1	EP 0911342	04/28/1999	PCT			
	B2	EP 0816380	01/07/1998	PCT			
	B3	EP 0873998	10/28/1998	PCT			
	B4	JP 11009269	01/19/1999	JP			
	B5	PCT/US85/01442	11/11/2003	PCT			
	B6	WO 90/14363	11/29/1990	PCT			
	B7	WO 96/34095	10/31/1996	PCT			
	B8	WO 98/28423	07/02/1998	PCT			
	B9	WO 98/54201	12/03/1998	PCT			
	B10	WO 99/29865	06/17/1999	PCT			
	B11	WO 99/65449	12/23/1999	PCT			
	B12	WO 99/65495	12/23/1999	PCT			
	B13	WO 01/23549	04/05/2001	PCT			
	B14	WO 02/15846	02/28/2002	PCT			

### OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Boyle v. Gorman and Mattson, Board of Patent Appeals and Interferences, Interference No. 104,336, Paper No. 39.
	C2	Camerini et al., "The T Cell Activation Antigen CD27 is a Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Gene Family", <i>J. Immunol.</i> , 147, 3165-3169 (1991).
	C3	Caux et al., "Activation of Human Dendritic Cells through CD40 Cross-linking", <i>J. Exp. Med.</i> , 180, 1263-1272 (1994).
	C4	Cooke, <i>Antisense &amp; Nucleic Acid Drug Dev.</i> , 8:115-122, 1998.
	C5	Craig et al., <i>Cell</i> , vol. 76, 1994

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449		Atty. Docket No. A-451N	Serial No. 10/825,898
<b>LIST OF REFERENCES CITED BY APPLICANT</b>		Applicant William J. Boyle	
(Use several sheets if necessary)		Filing Date April 15, 2004	Group 1644

C6	Dürkop et al., "Molecular Cloning and Expression of a New Member of the Nerve Growth Factor Receptor Family That Is Characteristic for Hodgkin's Disease", <i>Cell</i> , 68, 421-427 (1992).
C7	EMBL-EBI Database Entry HS421358, Accession No. W74421, Homo Sapiens cDNA Clone IMAGE:346544 3' Similar to Contains Alu Repetitive Element, Hillier et al., (June 1996).
C8	Galibert et al., "The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-Associated Factors in the Signaling Mechanisms of Receptor Activator of NF- $\kappa$ B, a Member of the TNFR Superfamily", <i>J. Biol. Chem.</i> , 273(51), 34120-34127 (1998).
C9	Goh et al., <i>Protein Engineering</i> , 4:785-791, 1991.
C10	Gray et al., "P-Element-Induced Recombination in <i>Drosophila melanogaster</i> . Hybrid Element Insertion", <i>Genetics</i> , 144(4):1601-1610 (1996).
C11	Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis", <i>Cell</i> , 66, 233-243 (1991).
C12	Jakobovits, Aya, <i>Current Opinion in Biotechnology</i> , 6:561-566, 1995.
C13	Johnson et al., "Expression and Structure of the Human NGF Receptor", <i>Cell</i> , 47, 545-554 (1986).
C14	Jones et al., <i>J. Cell Sci.</i> , Suppl 13:11-18, 1990.
C15	Kodaira et al., Cloning and characterization of the gene encoding mouse osteoclast differentiation factor", <i>Gene</i> , 230, 121-127 (1999).
C16	Kwon et al., "cDNA sequences of two inducible T-cell genes", <i>Proc. Natl. Acad. Sci. USA</i> , 86, 1963-1967 (1989).
C17	Lacey et al., <i>Cell</i> , 93:165-176, 1998.
C18	Lonberg, Nils et al., <i>Intern. Rev. Immunol.</i> , Vol 13, pp. 65-93, 1995.
C19	Mallett et al., "Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor", <i>EMBO J.</i> , 9, 063-1068 (1990).
C20	Nakagawa et al., "RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis", <i>Biochem. Biophys. Res. Commun.</i> , 253, 395-400 (1998).
C21	NCBI, Marra et al., The WashU-HHMI Mouse EST Project, GenBank Accession No. AA170348, (16 Feb. 1997).
C22	Romani et al., "Proliferating Dendritic Cell Progenitors in Human Blood", <i>J. Exp. Med.</i> , 180, 83-93 (1994).
C23	Rothe, M. et al., "The TNFR2-TRAF Signaling Complex Contains Two Novel Proteins Related to Baculoviral Inhibitor of Apoptosis Proteins", <i>Cell</i> , 83, 1243-1252 (1995).
C24	Schall, et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", <i>Cell</i> , 61, 61-370 (1990).
C25	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas", <i>EMBO J.</i> , 8, 1403-1410 (1989).
C26	Suda et al., "Modulation of Osteoclast Differentiation: Update 1995", <i>Endocr. Rev., Monograph</i> , 4(1), 266-270 (1995).

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449		Atty. Docket No. A-451N	Serial No. 10/825,898
<b>LIST OF REFERENCES CITED BY APPLICANT</b>		Applicant William J. Boyle	
(Use several sheets if necessary)		Filing Date April 15, 2004	Group 1644

	C27	Suda et al., "Modulation of Osteoclast Differentiation", <i>Endocr. Rev.</i> , 13, 66-80 (1992).
	C28	Suda, et al., <i>Bone</i> , 17:87S-91S, 1995.
	C29	Takahashi et al., <i>Biophys. Res. Comm.</i> , 256:449-455, 1999.
	C30	Tsukii et al., <i>Biochem. &amp; Biophys. Res. Comm.</i> , 246:337-341, 1998.
	C31	Viney et al., "Expanding Dendritic Cells In Vivo Enhances the Induction of Oral Tolerance", <i>J. Immunol.</i> , 160, 5815-5825 (1998).
	C32	Wong et al., "The TRAF Family of Signal Transducers Mediates NF- $\kappa$ B Activation by the TRANCE Receptor", <i>J. Biol. Chem.</i> , 273(43), 28355-28359 (1998).
	C33	Wong et al., "TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell-specific Survival Factor", <i>J. Exp. Med.</i> , 186, 2075-2080 (1997).
	C34	Wong et al., <i>J. Biol. Chem.</i> , 272:25190-25194, 1997.
	C35	Xu et al., "Targeted Disruption of TRAF3 Leads to Postnatal Lethality and Defective T-Dependent Immune Responses", <i>Immunity</i> , 5, 407-415 (1996).
	C36	Yun et al., "OPG/FDCR-1, a TNF Receptor Family Member, Is Expressed in Lymphoid Cells and Is Up-Regulated by Ligating CD40", <i>Immunol.</i> , 161, 6113-6121 (1998).

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	